Pluri Inc
NASDAQ:PLUR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.16
8.16
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PLUR stock under the Base Case scenario is 0.68 USD. Compared to the current market price of 5.45 USD, Pluri Inc is Overvalued by 87%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Pluri Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PLUR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Pluri Inc
Balance Sheet Decomposition
Pluri Inc
Current Assets | 31.1m |
Cash & Short-Term Investments | 30m |
Other Current Assets | 1.1m |
Non-Current Assets | 8.4m |
PP&E | 7.2m |
Other Non-Current Assets | 1.2m |
Current Liabilities | 4.5m |
Accounts Payable | 964k |
Accrued Liabilities | 2.5m |
Other Current Liabilities | 1m |
Non-Current Liabilities | 35m |
Long-Term Debt | 24m |
Other Non-Current Liabilities | 11m |
Earnings Waterfall
Pluri Inc
Revenue
|
326k
USD
|
Cost of Revenue
|
-4k
USD
|
Gross Profit
|
322k
USD
|
Operating Expenses
|
-22.5m
USD
|
Operating Income
|
-22.2m
USD
|
Other Expenses
|
1.3m
USD
|
Net Income
|
-20.9m
USD
|
Free Cash Flow Analysis
Pluri Inc
USD | |
Free Cash Flow | USD |
PLUR Profitability Score
Profitability Due Diligence
Pluri Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Pluri Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
PLUR Solvency Score
Solvency Due Diligence
Pluri Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Pluri Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PLUR Price Targets Summary
Pluri Inc
Dividends
Current shareholder yield for PLUR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PLUR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one PLUR stock under the Base Case scenario is 0.68 USD.
Compared to the current market price of 5.45 USD, Pluri Inc is Overvalued by 87%.